Taking stock of the drug industry, from the lab to the medicine chestJune 27, 2023Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Adobe STAT+ | FDA issues warning to wholesaler sued by Gilead and J&J for distributing counterfeit medicines The FDA cited Safe Chain Solutions for violating a federal law designed to bolster the integrity of the pharmaceutical supply chain. By Ed Silverman STAT+ | Lilly reaches $2.4 million settlement with EEOC over age discrimination lawsuit EEOC contended a Lilly executive made a presentation indicating the company's national workforce was "skewed toward the older generation." By Ed Silverman STAT+ | With Wegovy and Ozempic's success, can device makers keep up in the race to treat obesity? For the companies developing surgical tools and devices to treat obesity, new drugs present both an opportunity and an existential threat. By Lizzy Lawrence Adobe STAT+ | After late start, Eli Lilly has the momentum in battle for $30 billion weight loss market If its obesity pill and potent new injectable make it to market, Lilly is likely to take market share from Novo drugs like Wegovy. By Elaine Chen STAT+ | Grail faces uphill battle to get Medicare to cover its cancer screening test Medicare doesn't usually cover tests that screen healthy people, as Grail's cancer screening test Galleri does. By John Wilkerson More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments